• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Armed with Phase III win, Incyte eyes label expansion for Monjuvi

cafead

Administrator
Staff member
  • cafead   Aug 16, 2024 at 11:42: AM
via Incyte has announced positive topline data from the Phase III inMIND trial evaluating its CD19-targeting monoclonal antibody Monjuvi (tafasitamab) in patients with relapsed or refractory (r/r) follicular lymphoma.

article source
 

<